Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation From Donors After Cardiac Death

Trial Profile

Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation From Donors After Cardiac Death

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs BB 3 (Primary)
  • Indications Delayed graft function; Renal failure
  • Focus Therapeutic Use
  • Sponsors Angion Biomedica
  • Most Recent Events

    • 18 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 May 2016 as reported by ClinicalTrials.gov.
    • 18 Feb 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.
    • 18 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top